Cite
MDS-344: Pevonedistat Plus Azacitidine vs Azacitidine Alone in Higher-Risk Myelodysplastic Syndromes (MDS): Efficacy and Safety Results from Study P-2001 (NCT02610777)
MLA
Atanas Radinoff, et al. “MDS-344: Pevonedistat Plus Azacitidine vs Azacitidine Alone in Higher-Risk Myelodysplastic Syndromes (MDS): Efficacy and Safety Results from Study P-2001 (NCT02610777).” Clinical Lymphoma Myeloma and Leukemia, vol. 21, Sept. 2021, pp. S347–48. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........74174eb49b749efe8014805d5e4723a9&authtype=sso&custid=ns315887.
APA
Atanas Radinoff, Dan Zhao, Robert J. Fram, Sharon Friedlander, Dominik Selleslag, Kevin Galinsky, Maria Diez Campelo, Lionel Ades, Justin M. Watts, Douglas V. Faller, Montserrat Arnan, Nikolai Tzvetkov, Patricia Font Lopez, Joshua F. Zeidner, Carlos Graux, Marco Cerrano, Mikkael A. Sekeres, & Jane L. Liesveld. (2021). MDS-344: Pevonedistat Plus Azacitidine vs Azacitidine Alone in Higher-Risk Myelodysplastic Syndromes (MDS): Efficacy and Safety Results from Study P-2001 (NCT02610777). Clinical Lymphoma Myeloma and Leukemia, 21, S347–S348.
Chicago
Atanas Radinoff, Dan Zhao, Robert J. Fram, Sharon Friedlander, Dominik Selleslag, Kevin Galinsky, Maria Diez Campelo, et al. 2021. “MDS-344: Pevonedistat Plus Azacitidine vs Azacitidine Alone in Higher-Risk Myelodysplastic Syndromes (MDS): Efficacy and Safety Results from Study P-2001 (NCT02610777).” Clinical Lymphoma Myeloma and Leukemia 21 (September): S347–48. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........74174eb49b749efe8014805d5e4723a9&authtype=sso&custid=ns315887.